Astrana Health reported 56% revenue growth and 82% adjusted EBITDA increase in Q1 2026, prompting multiple price target hikes.
Baird increased its price target on Astrana Health (NASDAQ:ASTH) to $45 from $40, citing strengthening fundamentals and margin upside following Q1 2026 results. Needham also raised its target to $41 from $30, maintaining a Buy rating.
The company reported $965.1 million in revenue for Q1 2026, up 56% year over year. Adjusted EBITDA rose 82% to $66.3 million, while free cash flow surged 372% to $64.1 million. Results reflect growth in its integrated healthcare delivery platform.
Astrana Health operates as a risk-bearing healthcare management company, offering services including multi-specialty care, primary care, and radiology. The upgrades follow strong financial performance and improved margin trends.